Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
- 18 November 2009
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (1) , 231-238
Abstract
(2010). Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Current Medical Research and Opinion: Vol. 26, No. 1, pp. 231-238. doi: 10.1185/03007990903421994Keywords
This publication has 17 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a reviewInternational Journal Of Clinical Practice, 2007
- Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 DiabetesNew England Journal of Medicine, 2007
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2006
- Resistance to Insulin Therapy Among Patients and ProvidersDiabetes Care, 2005
- A Systematic Review of Adherence With Medications for DiabetesDiabetes Care, 2004
- Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 DiabetesDiabetes Care, 2004
- The Treat-to-Target TrialDiabetes Care, 2003
- Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort studyClinical Therapeutics, 2003
- Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. PopulationDiabetes Care, 2001